Riskpilot← Back to searchSign inGet full accessEva Holmberg Pharma Consulting AB
ABIn liquidationOrg 5568957764Business and other management consultancy activities · NACE 7022Est. 20120 employees
Revenue 2023
SEK 0
EBITDA margin
—
+67% vs 2022
Equity ratio
100.0%
Financial strength
Net profit 2023
SEK -1K
+67% vs 2022
| Revenue | SEK 0 | — |
| EBITDA | SEK -1K | +67% |
| Net profit | SEK -1K | +67% |
| Total assets | SEK 104K | -1% |
| Equity | SEK 104K | -1% |
| Employees | 0 | — |
Legal name
Eva Holmberg Pharma Consulting AB
Org number
5568957764
Legal form
Aktiebolag
NACE code
7022 · Business and other management consultancy activities
Founded
12 juni 2012
Share capital
SEK 56 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Aktiebolaget ska bedriva konsultverksamhet inom industrin, finansiell förvaltning, försäljning av jubileumsprodukter såsom ur och smycken till företag och offentliga myndigheter samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 478 | 676 | 340 | 2 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 107 | 73 | — | −3 | −1 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 107 | 73 | 0 | −3 | −1 |
| Net financials | −24 | −20 | — | — | — |
| Profit before tax | 94 | 62 | 0 | −3 | −1 |
| Tax | −20 | −13 | −0 | −0 | −0 |
| Net profit | 74 | 49 | 0 | −3 | −1 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 270 | 234 | 163 | 105 | 104 |
| Equity | 131 | 108 | 108 | 105 | 104 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 139 | 126 | 55 | 0 | 0 |
| Total debt | 139 | 126 | 55 | — | — |
EBITDA margin
-100000.0%
This company
15.8%
Market median
-633011% vs market
20192023
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20192023
Return on equity
-1.0%
This company
18.4%
Market median
-105% vs market
20192023
Net profit margin
-100000.0%
This company
8.1%
Market median
-1234668% vs market
20192023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192023
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EI Liquidator | Liquidator | 2024 |
| Name | Role | Member since |
|---|---|---|
| Former (5) | ||
| Deputy Board Member | 2020 – 2024 | |
| Deputy Board Member | 2020 – 2024 | |
| Chairman | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2024 | |
| Board of Directors | 2020 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Eva Holmberg Pharma Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eva Ingmari Furén | Liquidator | 0 companies |
| Jenny Eva Margareta Holmberg | Deputy Board Member | 0 companies |
| Anna Eva Margareta Holmberg | Deputy Board Member | 0 companies |
| Eva Ingeborg Holmberg | Chairman | 0 companies |
| Per Carl-Axel Holmberg | Deputy Board Member | 0 companies |
| Per Claes Uno Holmberg | Board of Directors | 0 companies |